Madhu Kumar
Stock Analyst at Goldman Sachs
(2.89)
# 1,501
Out of 4,820 analysts
153
Total ratings
54.46%
Success rate
18.79%
Average return
Main Sectors:
Stocks Rated by Madhu Kumar
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| JAZZ Jazz Pharmaceuticals | Initiates: Buy | $169 | $110.86 | +52.44% | 7 | Jun 5, 2024 | |
| FULC Fulcrum Therapeutics | Maintains: Neutral | $5 → $6 | $3.53 | +69.97% | 8 | Jan 26, 2024 | |
| INFA Informatica | Maintains: Neutral | $23 → $26 | $18.80 | +38.30% | 5 | Dec 7, 2023 | |
| UTZ Utz Brands | Maintains: Neutral | $19 → $17 | $13.38 | +27.06% | 2 | Nov 10, 2023 | |
| ALEC Alector | Initiates: Sell | $4 | $1.14 | +252.42% | 4 | Sep 25, 2023 | |
| KRYS Krystal Biotech | Maintains: Buy | $135 → $155 | $168.06 | -7.77% | 13 | May 22, 2023 | |
| CYTK Cytokinetics | Maintains: Buy | $48 → $53 | $40.43 | +31.09% | 4 | May 5, 2023 | |
| DSGN Design Therapeutics | Upgrades: Neutral | n/a | $3.89 | - | 3 | May 4, 2023 | |
| ARWR Arrowhead Pharmaceuticals | Maintains: Buy | $65 → $73 | $13.24 | +451.57% | 10 | May 3, 2023 | |
| APLS Apellis Pharmaceuticals | Maintains: Buy | $124 → $141 | $17.41 | +709.88% | 9 | Apr 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $39 → $34 | $13.32 | +155.26% | 6 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $20 → $6 | $3.51 | +70.94% | 8 | Dec 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $8 → $14 | $12.82 | +9.20% | 6 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $24 → $21 | $10.82 | +94.17% | 2 | Nov 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $5 | $14.88 | -66.40% | 3 | Aug 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $10 → $8 | $1.53 | +422.88% | 4 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $111 → $89 | $9.05 | +883.43% | 4 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $29 → $6 | $0.32 | +1,763.35% | 1 | Jan 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $10 | $0.40 | +2,396.88% | 1 | Aug 27, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $60 → $85 | $8.31 | +922.86% | 7 | Jun 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $23 → $39 | $1.55 | +2,416.13% | 3 | Mar 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $58 → $57 | $14.11 | +304.11% | 3 | Jul 31, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $3.29 | - | 15 | Jul 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $900 | $1.59 | +56,503.77% | 1 | Apr 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $17 → $20 | $6.06 | +230.03% | 2 | Mar 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $140 → $100 | $1.48 | +6,656.76% | 5 | Mar 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $35 | $32.82 | +6.64% | 1 | Mar 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $60 | $0.40 | +15,017.16% | 1 | Feb 11, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $58 → $40 | $6.37 | +527.94% | 2 | Sep 24, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $504 | $10.53 | +4,686.32% | 3 | Oct 8, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $210 → $230 | $251.56 | -8.57% | 2 | Aug 13, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $120 → $60 | $2.76 | +2,073.91% | 5 | Jul 6, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $40 | $1.31 | +2,953.44% | 1 | Feb 8, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $22 | $41.33 | -47.98% | 1 | Dec 1, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $38.29 | -38.63% | 1 | Mar 28, 2017 |
Jazz Pharmaceuticals
Jun 5, 2024
Initiates: Buy
Price Target: $169
Current: $110.86
Upside: +52.44%
Fulcrum Therapeutics
Jan 26, 2024
Maintains: Neutral
Price Target: $5 → $6
Current: $3.53
Upside: +69.97%
Informatica
Dec 7, 2023
Maintains: Neutral
Price Target: $23 → $26
Current: $18.80
Upside: +38.30%
Utz Brands
Nov 10, 2023
Maintains: Neutral
Price Target: $19 → $17
Current: $13.38
Upside: +27.06%
Alector
Sep 25, 2023
Initiates: Sell
Price Target: $4
Current: $1.14
Upside: +252.42%
Krystal Biotech
May 22, 2023
Maintains: Buy
Price Target: $135 → $155
Current: $168.06
Upside: -7.77%
Cytokinetics
May 5, 2023
Maintains: Buy
Price Target: $48 → $53
Current: $40.43
Upside: +31.09%
Design Therapeutics
May 4, 2023
Upgrades: Neutral
Price Target: n/a
Current: $3.89
Upside: -
Arrowhead Pharmaceuticals
May 3, 2023
Maintains: Buy
Price Target: $65 → $73
Current: $13.24
Upside: +451.57%
Apellis Pharmaceuticals
Apr 14, 2023
Maintains: Buy
Price Target: $124 → $141
Current: $17.41
Upside: +709.88%
Mar 1, 2023
Maintains: Buy
Price Target: $39 → $34
Current: $13.32
Upside: +155.26%
Dec 9, 2022
Downgrades: Neutral
Price Target: $20 → $6
Current: $3.51
Upside: +70.94%
Nov 10, 2022
Maintains: Sell
Price Target: $8 → $14
Current: $12.82
Upside: +9.20%
Nov 4, 2022
Maintains: Buy
Price Target: $24 → $21
Current: $10.82
Upside: +94.17%
Aug 25, 2022
Downgrades: Sell
Price Target: $5
Current: $14.88
Upside: -66.40%
May 24, 2022
Maintains: Sell
Price Target: $10 → $8
Current: $1.53
Upside: +422.88%
May 24, 2022
Maintains: Buy
Price Target: $111 → $89
Current: $9.05
Upside: +883.43%
Jan 19, 2022
Downgrades: Neutral
Price Target: $29 → $6
Current: $0.32
Upside: +1,763.35%
Aug 27, 2021
Downgrades: Sell
Price Target: $10
Current: $0.40
Upside: +2,396.88%
Jun 23, 2021
Maintains: Neutral
Price Target: $60 → $85
Current: $8.31
Upside: +922.86%
Mar 16, 2021
Upgrades: Outperform
Price Target: $23 → $39
Current: $1.55
Upside: +2,416.13%
Jul 31, 2020
Upgrades: Outperform
Price Target: $58 → $57
Current: $14.11
Upside: +304.11%
Jul 24, 2020
Downgrades: Neutral
Price Target: n/a
Current: $3.29
Upside: -
Apr 21, 2020
Initiates: Outperform
Price Target: $900
Current: $1.59
Upside: +56,503.77%
Mar 27, 2020
Maintains: Underperform
Price Target: $17 → $20
Current: $6.06
Upside: +230.03%
Mar 13, 2020
Maintains: Buy
Price Target: $140 → $100
Current: $1.48
Upside: +6,656.76%
Mar 12, 2020
Initiates: Outperform
Price Target: $35
Current: $32.82
Upside: +6.64%
Feb 11, 2020
Initiates: Outperform
Price Target: $60
Current: $0.40
Upside: +15,017.16%
Sep 24, 2019
Maintains: Buy
Price Target: $58 → $40
Current: $6.37
Upside: +527.94%
Oct 8, 2018
Upgrades: Buy
Price Target: $504
Current: $10.53
Upside: +4,686.32%
Aug 13, 2018
Maintains: Buy
Price Target: $210 → $230
Current: $251.56
Upside: -8.57%
Jul 6, 2018
Maintains: Neutral
Price Target: $120 → $60
Current: $2.76
Upside: +2,073.91%
Feb 8, 2018
Initiates: Buy
Price Target: $40
Current: $1.31
Upside: +2,953.44%
Dec 1, 2017
Reinstates: Buy
Price Target: $22
Current: $41.33
Upside: -47.98%
Mar 28, 2017
Initiates: Buy
Price Target: $24
Current: $38.29
Upside: -38.63%